Biotech Values

[DewDiligence]

The FDA staff citing its sole use of MNTA for its "expertise" during the heparin crisis strikes me as a fairly bullish sign for MNTA. If FDA staff views MNTA as having expertise, I don't think it's unreasonable to think that MNTA's generic Lovenox is likely being viewed in a better light by the FDA compared to the competition.

That’s why the numbers in the and fifth and sixth rows of the table in #msg-46038154 are small :- )

Actually, the FDA employed parties other than MNTA to solve the contaminated-heparin crisis: namely, an MIT team led by Professor Ram Sasisekharan: #msg-28748329. Of course, Sasisekharan happens to be a founder and director of MNTA (#msg-42166392) :- )